Stephan Stilgenbauer, M.D. University of Ulm (Germany)

Dr. Stephan Stilgenbauer received his medical training at Ruprecht-Karls Universität Heidelberg Medical School, Germany with electives in Hamilton, Canada; Jerusalem, Israel; Bath, UK and Cambridge, UK. He completed his final year at the Baylor College of Medicine and MD Anderson Cancer Center, Houston, Texas, USA. Dr. Stilgenbauer is currently associate Professor of Medicine at the Department of Internal Medicine III (Hematology, Oncology and Rheumatology) at the University of Ulm, Germany. His scientific activity is focused on the investigation of molecular factors in pathogenesis, prognosis and treatment of CLL and other lymphomas. He is the study co-ordinator of several trials of the German CLL Study Group with particular focus on risk-stratified therapy, stem cell transplantation, and refractory CLL. He is a member of the Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO), the European Association for Cancer Research (EACR) and the American Society of Hematology (ASH). He has authored or coauthored numerous original articles, reviews and book chapters in journals such as the N Engl J Med, Nature Medicine, J Clin Oncol, Blood, Leukemia, Oncogene, and Haematologica.